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Abstract 
Purpose: To evaluate the in-vivo antimalarial activity of the methanol extract of the leaves of Glyphaea 
brevis in Plasmodium berghei infected mice. 
Methods: The phytochemical profile of ethylacetate, n-butanol, and residual aqueous fractions of the 
methanol extract of G. brevis were determined using standard procedures. Mice, weighing between 15 - 
30 g, were used for this study.  Plasmodium berghei infected blood (0.2 ml) was used to infect each of 
55 mice (5 in 11 groups) intraperitoneally. Animals in the infected groups were treated orally with 
varying doses (200, 300 and 400 mg/kg body weight) of the ethylacetate, n-butanol and residual 
aqueous fractions daily, using artemisinin (5 mg/kg body weight per day) as standard drug, over a 
period of four days. The non-infected (normal control, n = 5) received distilled water (0.2 ml) while the 
infected control group (n = 5) was administered 0.2 ml normal saline. The suppressive antiplasmodial 
properties of the fractions as well as the serum concentrations of aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were determined. 
Results: Alkaloids, carbohydrates, cardiac glycosides, flavonoids, saponins, tannins, steroids and 
triterpenes were present in the extract fractions. The suppressive antiplasmodial activity of n-butanol, 
residual aqueous portion and ethylacetate fractions was 76.64, 73.25 and 72.99 %, respectively, while 
that of artemisinin was 86.13 %. The serum concentrations of AST, ALT, and ALP in the infected control 
group were significantly higher (p < 0.05) than those of the treated malaria-infected groups treated with 
the three fractions. 
Conclusion: Glyphaea brevis possesses significant antiplasmodial properties and could be a source of 
lead molecules for the development of new antimalarial agents.  
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Malaria, a disease caused by protistan parasites 
belonging to the genus Plasmodium, results from 
the multiplication of the parasite within red blood 
cells of the host, causing symptoms that typically 
include fever and headache, nausea and 
vomiting. In severe cases, this symptoms 
progress to anemia, coma or death, particularly 
among children and the elderly [1]. Like all 
malaria parasites of mammals, Plasmodium 
berghei is transmitted by Anopheles mosquitoes. 
The parasite has been an important element in 
the attempts to learn how to manage and 
eradicate malaria because of its extreme 
similarity in life cycle and infectious behavior, to 
malaria infections in humans. P. berghei's 
genetic map has been completed, bringing hope 
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that further understanding of all malarias will be 
possible, and the elements that cause P. berghei 
to be noninfectious to humans can be brought 
into play to deal with the malaria affecting 
humans [2]. 
 
Glyphaea brevis also called masquerade stick 
(common name), Aloanyansi (Ibo) or Atori 
(Yoruba) and Dorina (Hausa) has been reported 
to be used in the treatment of sleeping sickness 
and as an aphrodisiac. It possesses antibacterial, 
antioxidant and anti-inflammatory properties and 
beneficial effect in wound healing [3]. It is 
undoubtable that medicinal plants form the basic 
foundation of traditional medical practice 
worldwide; hence, the World Health Organization 
(WHO) encouraged the inclusion of herbal 
medicine of proven safety and efficacy in health 
care delivery programme in developing countries. 
In this respect, plant resources are potential 
targets for research and development of 
alternative malarial drugs, with novel modes of 
action [4]. Although the combinations of 
artemisinin and derivatives (ACTs) has been 
recommended for the treatment of malaria by the 
World Health Organization (WHO), resistance of 
malaria parasites to the drugs is now commonly 
reported [5]. This creates and urgent need for 
further research to develop new antimalarial 
drugs. The use of Glyphaea brevis in traditional 
medicine in the world to prevent or to cure 
malaria [6] lacks scientific evidence, hence the 




Chemicals and reagents 
 
N-butanol, ethylacetate and methanol were 
purchased from Sigma-Aldrich (Jos, Nigeria) 
while Giemsa stain powder and artemisinin 
(dihydroartemisinin tablets) were products of 
Bliss GVS Pharma (India) purchased from Okey 




This included light microscope (Olympus CH; 
magnification X 100/125160/0.17), glass slides, 
Sherwood Colorimeter 257, Grant JB Series 
Water Bath, Heraeus Labofuge 300 centrifuge, 
RS-232C weighing balance, Sysmex 





A total of eighty mice (60 males and 20 females) 
weighing between 15 - 30 g which were 
purchased from Nigeria Veterinary Research 
Institute, (VOM), Jos, Plateau State were used 
for this experiment. Twenty (20) of these mice 
were infected with Plasmodium berghei using 
blood samples of mice (obtained from National 
Institute of Medical Research (NIMR), Lagos, 
Nigeria) newly infected with P. berghei.  All 
animals were housed in well-ventilated cages, 
allowed to acclimatize for two weeks, and were 
fed on commercial laboratory diet and water ad 
libitum. Study protocols and ethical issues were 
approved by the University Research and Ethical 
Committee (number: sci10-11/10604) of Ahmadu 
Bello University, Zaria, and animals were 
handled in conformity with internationally 
accepted laboratory animal use and care 
guidelines [7]. 
 
Plant collection and identification 
 
Leaves of Glyphaea brevis were collected from 
farmland in Irun Akoko, Ondo State, Nigeria and 
the plant was identified by a taxonomist, Gallah 
UJ, at the herbarium unit of Biological Sciences 
Department, Ahmadu Bello University, Zaria 
where a voucher specimen number 2634 was 
deposited for future reference.  
 
Preliminary extraction of plant material and 
fractionation of plant extract 
 
Leaves of G. brevis were air dried, reduced to 
coarse powder using wooden mortar and pestle. 
Coarsely powdered leaves (100 g) were 
extracted with 500 ml of methanol by cold 
maceration and left for 48 h. The extract was 
filtered and evaporated to dryness using rotary 
evaporator. The methanol extract was then 
suspended in 1 L of distilled water and the filtrate 
was partitioned in separating funnel with 750 ml 
of ethyl acetate. Resultant ethyl acetate fraction 
was concentrated on a water bath and the 
aqueous portion was further partitioned with 750 
ml of n-butanol to get the n-butanol fraction after 
concentration [8]. The fractions were stored in 
suitable containers until ready for use. 
 
Preliminary phytochemical screening 
 
Phytochemical screening to determine the 
constituent of the plant extract was carried out by 
the method described by Sofowora [9] and 
Trease and Evans [10]. 
 
Acute toxicity (LD50) test 
 
The mean lethal dose of the three fractions 
(ethylacetate, n-butanol, residual aqueous 
fractions) of the extract of G. brevis were 
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determined in mice (weighing between 15-30 g) 
using the method described by Lorke [11]. 
 
In vivo antiplasmodial determination 
 
The antimalarial property of the plant was 
evaluated by determining its suppressive 
antiplasmodial properties in-vivo using the 
method of Bulus et al [12]. For this purpose the 
60 mice were divided into 12 different groups of 
five mice each. The mice in 11 of the groups 
were infected with the parasites by inoculating 
them with 0.2 ml of blood sample obtained from 
the mice infected with P. berghei. Mice in group I 
served as normal control and were not infected 
with P. berghei or treated with the plant extract 
but all other mice were infected with P. berghei. 
The mice in group II served as positive control 
and were not treated. Animals in group III were 
treated with 5 mg/kg standard artemisinin 
(standard control) while those in groups IV, V, X 
were treated with 200 mg/kg body weight of the 
ethylacetate, n-butanol and residual aqueous 
fractions. The mice in groups VI, VII, XI and 
those in groups VIII, IX, XII were treated with 300 
mg/kg and 400 mg/kg body weight of the various 
extracts, respectively. The first treatment started 
3 h after parasite inoculation, and the others 
were given at the same time on the following 
days for four consecutive days. On the fifth day, 
samples of blood was collected from the caudal 
vein of each mouse on to a clean glass slide and 
stained with Giemsa stain after which the number 
of the parasitized cells was determined 
microscopically and the percentage suppression 
determined using Eq 1. 
 
Mean suppression (%) = {(APC – APT)/APC}100 …(1) 
 
where APC is the average number of 
parasitaemia in the positive control and APT is 
the average number of parasitaemia in the test 
group [12]. At the end of the experiments, the 
animals were sacrificed and blood samples were 
collected, centrifuged and used for further 
analysis. 
 
Determination of biochemical parameters 
 
The estimation of packed cell volume (PCV) was 
carried by microhaematocrit method of Alexander 
and Grifiths [13]. Serum concentrations of 
aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were assayed by the 
method of Reitman and Frankel [14] while 
alkaline phosphatase (ALP) was determined 




Data obtained were expressed as means ± SD 
except where otherwise stated. Statistical 
comparison was carried out using one way 
analysis of variance (ANOVA) and Duncan 
Multiple Range Test. P < 0.05 was considered to 




Phytochemical screening of the different fractions 
of G. brevis showed the presence of alkaloids, 
carbohydrates, cardiac glycosides, flavonoids, 
saponins, tannins, steroids and triterpenes. 
Saponin was absent in the ethylacetate fraction 
and steroids were absent in both n-butanol and 
residual aqueous fractions. 
 
Antiplasmodial activity of Glyphaea brevis  
 
The fractions exhibited significant dose-
dependent (p < 0.05) parasitaemia suppressive 
activity for the various fractions with n-butanol 
fraction having the highest suppressive activity 
on the parasites (Figure 1). The ethylacetate, n-
butanol, and residual aqueous fractions caused 
72.99 %, 76.64 % and 73.25 % suppression, 
respectively, in parasitaemia of P. berghei 
infected mice with n-butanol having the highest 
suppressive activity while Artemisinin (a standard 
antimalaria drug) exerted 86.13 % suppression. 
 
Table 1: Phytochemical profile for methanol fractions of Glyphaea brevis leaf extract 
 
Class *EtAcFx *N-ButFx *ReAqFx 
Alkaloids + + + 
Carbohydrates                + + + 
Cardiac glycosides             + + + 
Flavonoids + + + 
Saponins       - + + 
Tannins + + + 
Steroids + - - 
Triterpenes + + + 
*EtAcFx: Ethylacetate Fraction, *N-ButFx: N-Butanol Fraction, *ReAqFx : Residual aqueous Fraction; where + 
represent positive; - represent negative 
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Figure 1: Percentage suppression of various fractions of methanolic extract of Glyphaea brevis on Plasmodium 
berghei infected mice (       ethyl acetate fraction,        n-buyanol fraction,        aqueous fraction) 
 
Effects of Glyphaea brevis leaf fractions on 
serum liver function  
 
The serum levels of AST, ALT and ALP were 
significantly higher in the positive controls than 
the enzyme levels in the P. berghei infected mice 
treated with the fractions of the extracts (Tables 
2-3).  Table 4, however, indicated significant 
decrease (p < 0.05) in the level of the liver 
enzymes (ALT, AST and ALP) in the positive 
control group when compared with those from 
the animals treated with the fractions of the 
extracts. 
 
The residual-aqueous fraction treated group of 
mice showed a higher increase in the serum 
concentration of these liver enzymes than the 
positive control group. However, the toxicological 
profiling of the fractions of the extract indicated 
that oral median lethal dose was above 5000 




The methanol extract of the leaves of Glyphaea 
brevis has demonstrated significant dose 
dependent suppression of parasitaemia in P. 
berghei infected mice. Alkaloids, carbohydrates, 
cardiac glycosides, flavonoids, saponins, tannins, 
steroids and triterpenes were found to be present 
in the plant extract. The oral median lethal dose 
of the extract was above 5000 mg/kg body 
weight indicating that the plant extract is 
relatively safe and a good candidate for further 
studies for antimalarial medicine. 
 
Although the mechanism of antiplasmodial action 
of this extract has not been elucidated, antiplas- 
 
 
Table 2:  Effect of ethylacetate fraction of Glyphaea brevis extract on the activities of hepatic marker enzymes in 
Plasmodium berghei infected mice 
 
Treatment (mg/kg) AST (IU/L) ALT (IU/L) ALP (IU/L) 
Normal Control (Distilled H2O) 41.00 ± 3.03a 48.33 ± 11.06a 64.00 ± 6.56a 
Positive Control (0.2 ml Normal saline) 96.67 ± 63.61b 157.33±124.60b 88.33 ±11.02c 
Standard Control 
(5 mg/kg Artemisinin) 
54.00 ± 6.08ab 62.33 ± 10.21a 74.33 ± 4.62abc 
200 mg/kg (Ethylacetate fraction) 44.25 ± 8.54a 60.00 ± 7.55a 71.33 ±8.39ab 
300 mg/kg (Ethylacetate fraction) 57.33 ± 25.15ab 68.33 ± 23.03ab 85.33 ±5.13bc 
400 mg/kg (Ethylacetate fraction) 66.00 ± 16.52ab 81.33 ± 11.93ab 74.67 ± 6.35abc 
Values are expressed as mean ± SD (standard deviation).Values with different superscripts down the columns 
are significantly different (p < 0.05); where AST: aspartate aminotransferase; ALT: alanine aminotransferase; 
ALP: alkaline phosphatase 
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Table 3: Effect of n-butanol fraction of Glyphaea brevis extract on the level of hepatic marker enzymes in 
Plasmodium berghei-infected mice 
 
Treatment (mg/kg) AST (IU/L) ALT (IU/L) ALP (IU/L) 
Normal Control (Distilled H2O) 41.00 ± 6.06a 48.33± 11.06a 64.00 ± 6.56a 
Positive Control (0.2 ml normal saline) 96.67 ± 63.61b 157.33±124.60b 88.33 ± 11.02c 
Standard Control (5 mg/kg artemisinin) 54.00 ± 6.08a 62.33 ± 10.21a 74.33 ±4.62ab 
200 mg/kg (N-butanol fraction) 63.50 ± 16.05ab 71.33 ± 12.66ab 84.67 ± 4.04bc 
300  mg/kg (N-butanol fraction) 54.60 ± 15.21a 58.00 ± 2.00a 67.25 ± 1.26a 
400 mg/kg (N-butanol fraction) 59.75 ± 7.37ab 69.33 ± 18.82ab 83.25 ± 2.22bc 
Values are expressed as mean ± SD (standard deviation). Values with different superscripts down the  columns 
are significantly different (p < 0.05); where AST: aspartate aminotransferase; ALT: alanine aminotransferase; 
ALP: alkaline phosphatase 
 
Table 4: Effect of residual aqueous fraction of Glyphaea brevis Extract on the activities of hepatic marker 
enzymes in Plasmodium berghei-infected Mice 
 
Treatment (mg/kg) AST (IU/L) ALT (IU/L) ALP (IU/L) 
Normal Control (Distilled H2O) 41.00 ± 6.06a 48.33± 11.06a 64.00 ± 6.56a 
Positive Control (0.2 ml Normal saline) 96.67 ± 63.61a 157.33 ± 124.60ab 88.33 ±11.01cd 
Standard Control (5 mg/kg Artemisinin) 54.00 ± 6.08a 62.33 ± 10.21a 74.33 ± 4.62abc 
200 mg/kg (Residual Aqueous fraction) 78.33 ± 8.33a 81.67 ± 8.02a 71.33 ± 4.93ab 
300  mg/kg (Residual Aqueous fraction) 198.33 ± 79.43b 235.00 ± 86.26b 102.00 ± 8.89de 
400 mg/kg (Residual Aqueous fraction ) 191.33 ± 41.77b 231.00 ± 45.83b 110.00 ± 10.15e 
Values are expressed as mean ± SD (standard deviation). Values with different superscripts down the columns 
are significantly different (p < 0.05); where AST: aspartate aminotransferase; ALT: alanine aminotransferase; 
ALP: alkaline phosphatase 
 
modial effects of natural plant products have 
previously been attributed to some of their active 
phytochemical components including alkaloids, 
flavonoids and terpenes. Some of the 
phytochemicals such as terpenes and flavonoids 
detected the extract have been earlier reported 
to have antiplasmodial activity [16].  
 
Many published works [17-20] have investigated 
biochemical alteration in malaria infection and 
reported significant alteration (p < 0.05) in 
biochemical variables. The observed elevations 
of serum concentration of ALT, AST and ALP in 
the positive control group of the mice are 
indications of liver damage in the mice when 
compared to the animals treated with fractions of 
the extracts. These findings conform to the 
pathogenesis of P. berghei infection and 
correlates particularly with the work of Onyesom 
and Onyemakonor [21]. The increase in 
concentration of the liver enzymes in mice 
treated with the residual-aqueous fraction 
compared with the positive control group 
indicates that the fraction may have some 
hepatotoxic effect. However, the median lethal 
dose which was above 5000 mg/kg is indicates 




N-Butanol and ethylacetate fractions of the 
methanol extract of G. brevis possesses 
antiplasmodial activity against P. berghei-
infected mice. Toxicological profile indicates that 
the fractions are safe. However, the mechanism 
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